Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 24 Parkinson's papers of 516 | 0.58 |
| pathways Reactome | 1 pathway; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 7597
Sealed predictions
- FUNDC1 in dopamine neurons, braak+0.47 (p 0.202) → +0.44 (p 0.240)receipt 7604
Swarm cases
receipt 7604: FUNDC1 in dopamine neurons, braak
- power
- full sample +0.38 (p 0.118, n 18), 95% CI -0.10 to +0.72. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.51 (p 0.032, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.48 (p 0.045, n 18). not the mix.
- skeptic
- leave-one-out range +0.30 to +0.51, sign flips 0; without severely affected donors +0.38 (p 0.118, n 18). fragile.
- cell type
- strongest in OPCs: -0.74 (p 4.7e-4, n 18) vs +0.38 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FUNDC1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up FUNDC1 · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.20 p 0.477 (needs p < 2.8e-4)
Receipts
loading the receipts